Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer's disease: A nationwide population-based cohort study

被引:19
作者
Lee, Hyun Woo [1 ,2 ,3 ,4 ]
Kim, Seungyeon [5 ]
Jo, Youngkwon [3 ,4 ]
Kim, Youjin [3 ,4 ]
Ye, Byoung Seok [6 ]
Yu, Yun Mi [1 ,2 ,3 ,4 ]
机构
[1] Yonsei Univ, Coll Med, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea
[2] Yonsei Univ, Coll Pharm, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea
[3] Yonsei Univ, Coll Pharm, Dept Pharm, Incheon, South Korea
[4] Yonsei Univ, Yonsei Inst Pharmaceut Sci, Coll Pharm, Incheon, South Korea
[5] Dankook Univ, Coll Pharm, Cheonan, South Korea
[6] Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea
来源
FRONTIERS IN AGING NEUROSCIENCE | 2023年 / 15卷
基金
新加坡国家研究基金会;
关键词
Alzheimer's disease; renin-angiotensin system; angiotensin II receptor blocker; blood-brain barrier; neuroprotective agents; CONVERTING ENZYME-INHIBITORS; COGNITIVE DECLINE; PPAR-GAMMA; TYPE-2; RECEPTOR; DEMENTIA; HYPERTENSION; ASSOCIATIONS; TELMISARTAN; SYSTEM; ACE;
D O I
10.3389/fnagi.2023.1137197
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
BackgroundRecent studies on renin-angiotensin system (RAS) inhibitors have reported a reduced risk of Alzheimer's disease (AD). Nevertheless, the effect of RAS inhibitor type and blood-brain barrier (BBB) permeability on the risk of AD is still unknown. ObjectivesTo assess the effects of RAS inhibitors on the risk of AD based on the type and BBB permeability and investigate the cumulative duration-response relationship. MethodsThis was a population-based retrospective cohort study using the Korean Health Insurance Review and Assessment database records from 2008 to 2019. The data of patients diagnosed with ischemic heart disease between January 2009 and June 2009 were identified for inclusion in the analyses. Propensity score matching was used to balance RAS inhibitor users with non-users. The association between the use of RAS inhibitors and incident AD was evaluated using a multivariate Cox proportional hazard regression model. The results are presented in adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). ResultsAmong the 57,420 matched individuals, 7,303 developed AD within the follow-up period. While the use of angiotensin-converting enzyme inhibitors (ACEIs) was not significantly associated with AD risk, the use of angiotensin II receptor blockers (ARBs) showed a significant association with reduced risk of incident AD (aHR = 0.94; 95% CI = 0.90-0.99). Furthermore, the use of BBB-crossing ARBs was associated with a lower risk of AD (aHR = 0.83; 95% CI = 0.78-0.88) with a cumulative duration-response relationship. A higher cumulative dose or duration of BBB-crossing ARBs was associated with a gradual decrease in AD risk (P for trend < 0.001). No significant association between the use of ACEIs and the risk of AD was observed regardless of BBB permeability. ConclusionLong-term use of BBB-crossing ARBs significantly reduced the risk of AD development. The finding may provide valuable insight into disease-modifying drug options for preventing AD in patients with cardiovascular diseases.
引用
收藏
页数:12
相关论文
共 73 条
  • [1] Role of brain renin angiotensin system in neurodegeneration: An update
    Abiodun, Oyesiji A.
    Ola, Mohammad Shamsul
    [J]. SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2020, 27 (03) : 905 - 912
  • [2] Possible combined effect of perindopril and Azilsartan in an experimental model of dementia in rats
    Alzahrani, Yahya M.
    Sattar, Mai A. Alim A.
    Kamel, Fatemah O.
    Ramadan, Wafaa S.
    Alzahrani, Yahya A.
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2020, 28 (05) : 574 - 581
  • [3] Alzheimers Disease International, 2019, WORLD ALZHEIMER REPO
  • [4] The Alzheimer's Disease Clinical Spectrum Diagnosis and Management
    Atri, Alireza
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (02) : 263 - +
  • [5] Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
    Austin, Peter C.
    [J]. PHARMACEUTICAL STATISTICS, 2011, 10 (02) : 150 - 161
  • [6] Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
    Bachurin, Sergey O.
    Bovina, Elena V.
    Ustyugov, Aleksey A.
    [J]. MEDICINAL RESEARCH REVIEWS, 2017, 37 (05) : 1186 - 1225
  • [7] Alzheimer's disease
    Ballard, Clive
    Gauthier, Serge
    Corbett, Anne
    Brayne, Carol
    Aarsland, Dag
    Jones, Emma
    [J]. LANCET, 2011, 377 (9770) : 1019 - 1031
  • [8] Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity
    Benson, SC
    Pershadsingh, HA
    Ho, CI
    Chittiboyina, A
    Desai, P
    Pravenec, M
    Qi, NN
    Wang, JM
    Avery, MA
    Kurtz, TW
    [J]. HYPERTENSION, 2004, 43 (05) : 993 - 1002
  • [9] The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity
    Berthold, Douglas
    Joyce, Geoffrey
    Wharton, Whitney
    Kehoe, Patrick
    Zissimopoulos, Julie
    [J]. PLOS ONE, 2018, 13 (11):
  • [10] The anticholinergic drug scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity
    Carnahan, Ryan M.
    Lund, Brian C.
    Perry, Paul J.
    Pollock, Bruce G.
    Culp, Kennith R.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (12) : 1481 - 1486